New vaccine shows promise in rare eye cancer trial
NCT ID NCT04335890
First seen Mar 17, 2026 · Last updated May 08, 2026 · Updated 8 times
Summary
This early-phase trial tested a personalized vaccine made from a patient's own immune cells and tumor material for metastatic uveal melanoma, a rare eye cancer. Seventeen adults received the vaccine alongside standard treatments like immunotherapy or chemotherapy. The main goals were to check safety and find the best dose, while also looking at whether the vaccine could boost the immune system to fight the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA, UVEAL METASTATIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University Hospital Erlangen Dept. of Dermatology
Erlangen, Bavaria, 91054, Germany
Conditions
Explore the condition pages connected to this study.